Ranolazine for Congenital Long QT Syndrome Type III (LQT3): Experimental and Long-Term Clinical Data

BACKGROUND: The basic defect in long QT syndrome type-III (LQT3) is an excessive inflow of sodium current during phase-3 of the action potential caused by mutations in the SCN5A gene. Most sodium channel blockers reduce the early (peak) and late components of the sodium current (I(Na) and I(NaL)) bu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Circ Arrhythm Electrophysiol
Hlavní autoři: Chorin, Ehud, Hu, Dan, Antzelevitch, Charles, Hochstadt, Aviram, Belardinelli, Luiz, Zeltser, David, Barajas-Martinez, Hector, Rozovski, Uri, Rosso, Raphael, Adler, Arnon, Benhorin, Jesaia, Viskin, Sami
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5119553/
https://ncbi.nlm.nih.gov/pubmed/27733495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCEP.116.004370
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky